文献速递妇科

美国子宫内膜癌子宫切除术中腹腔细胞学检查的趋势

Trends in peritoneal cytology evaluation at hysterectomy for endometrial cancer in the United States.
PubMed 文献 · Gynecol Oncol · 2021-03-13

本研究基于SEER数据库回顾性分析2010至2017年62,809例子宫内膜癌子宫切除术患者,发现腹腔细胞学检查率从75.5%降至64.9%(P<0.001),2017年较2010年调整比值比为0.56(95%CI 0.52-0.60),且该检查与全因死亡率改善相关(HR 0.94,95%CI 0.89-0.99)。

要点

  • 2009年分期修订后,美国子宫内膜癌术中腹腔细胞学检查率逐年下降。
  • 腹腔细胞学检查与全因死亡率改善相关,尤其在子宫内膜样组织学亚组。
  • 当前NCCN和FIGO指南仍推荐子宫切除术时评估腹腔细胞学。

核心结论

  • 2009年分期修订后,美国子宫内膜癌子宫切除术中腹腔细胞学采样逐渐减少。
  • 腹腔细胞学评估可能与特定肿瘤组的生存改善相关。

研究设计与样本

  • 回顾性观察研究,查询SEER项目,纳入2010至2017年接受子宫切除术的I-III期子宫内膜癌女性。
  • 共62,809名女性,其中43,873名(69.9%)术中进行了腹腔细胞学评估,18,936名(30.1%)未进行。

主要发现

  • 腹腔细胞学评估利用率在研究期间从75.5%下降至64.9%(P < 0.001)。
  • 多变量分析中,较近的手术年份独立与腹腔细胞学实施可能性降低相关(2017年 vs 2010年调整比值比0.56,95%置信区间0.52-0.60)。
  • 子宫切除术时腹腔细胞学评估与全因死亡率改善相关(全队列风险比0.94,95%置信区间0.89-0.99;子宫内膜样组织学风险比0.90,95%置信区间0.84-0.97)。

关键数值与推荐

  • 2009年FIGO修订子宫内膜癌分期标准,将腹腔细胞学从分期标准中移除。
  • 当前NCCN指南和FIGO组织推荐子宫切除术时评估腹腔细胞学。

临床怎么用

  • 临床实践中应知晓腹腔细胞学检查率下降的趋势。
  • 对于特定肿瘤组,可考虑子宫切除术时进行腹腔细胞学评估以获取预后信息。

局限性

  • 回顾性观察性研究设计,可能存在残余混杂。
  • 未报告其他潜在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The collection of a peritoneal cytologic sample at the time of surgery for endometrial cancer has traditionally been an important part of surgical staging. In 2009, the International Federation of Gynecology and Obstetrics revised the cancer staging schema for endometrial cancer and removed peritoneal cytology from the staging criteria. The current National Comprehensive Cancer Network guidelines and the International Federation of Gynecology and Obstetrics organization, however, recommend evaluation of peritoneal cytology at the time of hysterectomy. This study examined population-based trends, characteristics, and outcomes of peritoneal cytologic sampling for endometrial cancer surgery following the 2009 staging revision in the United States. METHODS: This is a retrospective observational study querying the Surveillance, Epidemiology, and End Results Program to examine women with stage I-III endometrial cancer who underwent hysterectomy from 2010 to 2017. Trends, characteristics, and survival associated with peritoneal cytologic evaluation at the time of hysterectomy were assessed in multivariable analysis and with propensity score weighting. RESULTS: Among 62,809 women who underwent hysterectomy, 43,873 (69.9%) had peritoneal cytologic evaluation at surgery and 18,936 (30.1%) did not. Utilization of peritoneal cytologic evaluation decreased from 75.5% to 64.9% during the study period (P < 0.001). In multivariable analysis, more recent year of surgery was independently associated with a decreased likelihood of performance of peritoneal cytology (adjusted-odds ratio of peritoneal cytology evaluation in 2017 versus 2010 0.56, 95% confidence interval [CI] 0.52-0.60). Peritoneal cytologic evaluation at the time of hysterectomy was associated with improved all-cause mortality (hazard ratio in the whole cohort 0.94, 95%CI 0.89-0.99; and hazard ratio in endometrioid histology 0.90, 95%CI 0.84-0.97). CONCLUSION: Performance of peritoneal cytologic sampling has gradually decreased following the 2009 staging revision in the United States. Our study suggests that peritoneal cytology evaluation at hysterectomy may be associated with improved survival in certain tumor groups.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Matsuo K, Klar M, Harter P, et al. Trends in peritoneal cytology evaluation at hysterectomy for endometrial cancer in the United States. Gynecol Oncol. 2021. PMID: 33726962. doi:10.1016/j.ygyno.2021.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。